DrugBiological
Teplizumab clinical trials
Also written MGA031, TZIELD and SAR446681.
- studies test it
- 13
- open now
- 3
- in phase 3
- 4
- first study started
- 2002
Keep track of what changes. Save the teplizumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2006 (2); 1 more planned to start later
| Year | Studies |
|---|---|
| 2002 | 1 |
| 2006 | 2 |
| 2009 | 2 |
| 2010 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2023 | 1 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 8
- Phase 3
- 4
- Phase 4
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 9 · Other 4
Sanofi (3) · MacroGenics (3) · National Institute of Allergy and Infectious Diseases (NIAID) (2) · Provention Bio, a Sanofi Company (1) · Provention Bio, Inc. (1) · Precigen Actobio T1D, LLC (1) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) · Abdullah Kars (1)
Often tested with
Tested in the same studies.
AG019 (1)
Studies
Open first, then newest update. How each study uses teplizumab is read from its arms, and is right about nine times in ten.
Testing it · 13
- Efficacy and Safety of Teplizumab in Japanese Participants With Stage 2 Type 1 DiabetesRecruitingPhase 2SanofiNCT06791291Written as Teplizumab
- A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 DiabetesRecruitingPhase 3SanofiNCT07088068Written as Teplizumab
- Sequential Immune Modulation and Antigen-Specific Tolerance Induction for Disease Modification in Recent-Onset Type 1 DiabetesNot yet recruitingPhase 1Abdullah KarsNCT07610213Written as Teplizumab
- Teplizumab in Pediatric Stage 2 Type 1 DiabetesCompletedPhase 4SanofiNCT05757713Written as teplizumab
- At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)CompletedPhase 2Provention Bio, a Sanofi CompanyNCT04270942Written as teplizumab 1 mg/mL
- Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of TeplizumabCompletedPhase 3Provention Bio, Inc.NCT03875729Written as teplizumab
- Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes MellitusTerminatedPhase 3MacroGenicsNCT00920582Written as Teplizumab Herold Regimen
- The Protégé Study - Clinical Trial of MGA031 in Children and Adults With Recent-Onset Type 1 Diabetes MellitusCompletedPhase 2/3MacroGenicsNCT00385697Written as Teplizumab
- A Study to Assess the Safety and Tolerability of Different Doses of AG019 Administered Alone or in Combination With Teplizumab in Participants With Recent-onset Diagnosed Type 1 Diabetes (T1D)CompletedPhase 1/2Precigen Actobio T1D, LLCNCT03751007Written as Teplizumab
- Safety Study of the Monoclonal Antibody Teplizumab (MGA031) in Subjects With Moderate or More Severe PsoriasisTerminatedPhase 1/2MacroGenicsNCT00954915Written as teplizumab
- Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"CompletedPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT01030861Written as Teplizumab
- PsA Treatment With hOKT3γ1 (Ala-Ala)TerminatedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00239720Written as hOKT3gamma1(Ala-Ala)
- Treatment With hOKT3gamma1(Ala-Ala) in T1DMTerminatedPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT00806572Written as hOKT3gamma1(Ala-Ala)
As the comparator · 1 — what is tested is compared with teplizumab
Codes
What other systems call teplizumab · ClinicalTrials.gg INT004800
- MeSH (NLM) C502540teplizumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) S4M959U2IJTEPLIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2621880One source FDA
- Wikidata Q7701358teplizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C88647TeplizumabOne source FDA
- DrugBank DB06606One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C502540 | teplizumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | S4M959U2IJ | TEPLIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2621880 | — | One source FDA |
| Wikidata | Q7701358 | teplizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C88647 | Teplizumab | One source FDA |
| DrugBank | DB06606 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.